Regulatory milestones

BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down $0.45 to $5.15 last week after FDA accepted for review an NDA for Bunavail buprenorphine naloxone to treat opioid dependence. The company expects a decision by early June 2014. The NDA was submitted under section 505(b)(2) of the Food, Drug and Cosmetic Act.